Ligand gains new Buy from BofA on high-margin, less risky narrative

Ligand Pharmaceuticals has received a new 'Buy' rating from Bank of America, citing the company's high-margin exposure to biopharma growth and a less risky business narrative.

11 Mar, 13:06 — 11 Mar, 17:49

Post Share

Why this matters

Analyst ratings from major financial institutions like Bank of America can significantly influence investor perception and stock performance. A 'Buy' rating suggests that analysts believe the stock will outperform, potentially leading to increased investor interest and share price appreciation.

Key entitiesLigand Pharmaceuticals Bank of America (BofA)

The Story

What 2 sources agree on, dispute, and miss

What sources agree on

Bank of America (BofA) issued a new 'Buy' rating for Ligand Pharmaceuticals
BofA's rating is based on Ligand's high-margin business model
BofA views Ligand as having a less risky narrative

Key claims3 agreed

✓

Ligand Pharmaceuticals offers high-margin exposure to biopharma growth

agreed·Yahooseeking-alpha

✓

BofA initiated a 'Buy' rating on Ligand Pharmaceuticals

agreed·Yahooseeking-alpha

✓

Ligand Pharmaceuticals has a less risky narrative

agreed·Yahooseeking-alpha

The Story

Analyzing sources…

Source Diversity

Moderate (27/100)

2 sources— more sources would strengthen this score15/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left1

Left (1)

Yahoo

Center

Right1

Right (1)

seeking-alpha

Far R

Geographic diversity— 1 region4/34

US2

ℹAll sources from US region

ℹOnly 2 sources cover this story

Sources

Showing 2 of 2 sources

YahooMostly Factual28d ago

Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says

Read full article →

seeking-alphaMixed28d ago